Contineum Therapeutics : PIPE-791 Phase 1b Chronic Pain Trial Topline Data Supplemental Information

Published: 2026-04-30 17:48:49 ET CTNM

Published on 04/30/2026 at 05:48 pm EDT

PIPE-791 Phase 1b Chronic Pain Trial Topline Data Supplemental Information

April 30, 2026

Consistent Improvement Across Multiple Exploratory Pain Measures

Phase 1b randomized, double-blind, placebo-controlled, 4-week, crossover trial enrolled 43 patients - 23 chronic osteoarthritis pain (COAP) and 20 chronic lower back pain (CLBP)

Favorable safety and tolerability demonstrated at the once-daily 10mg oral dose in the largest patient population and longest treatment duration studied to date

Most treatment emergent adverse events (TEAEs) were mild to moderate; no serious adverse events (SAEs) reported

No clinically meaningful changes in vital signs, including mean changes in blood pressure (BP) or clinically-relevant orthostatic events

Encouraging trends observed across multiple exploratory efficacy endpoints including improvements in measures of pain and other functional patient-reported outcomes; particularly as it relates to COAP

Patients treated with PIPE-791 largely demonstrated numerical improvements from baseline in weekly average of average daily pain and worst pain using the 11-point Pain-Intensity Numerical Rating Scale (PI-NRS)

We believe these data support further evaluation and development of

PIPE-791 for the potential treatment of chronic pain

Primary endpoint for safety & tolerability

Crossover Placebo

Multiple exploratory endpoints for pain assessment

Treatment Period 1 (TP1)

Treatment Period 2 (TP2)

Run-in (baseline)

Wash-out

PIPE-791 (10 mg, QD)

(2)

COAP, n = 22

CLBP, n = 20

PIPE-791 (10 mg, QD)

Placebo

Safety Followup

14 days 7 day 28 day 28 day

COAP, n = 21

CLBP, n = 19

(3)

https://clinicaltrials.gov/study/NCT06810245

A single participant with COAP (assigned to Placebo/PIPE 791) withdrew consent in TP1 and is not included in the TP1 full analysis set.

Two participants (one with COAP and one with CLBP, both assigned to PIPE-791/Placebo) discontinued treatment in TP1, never received placebo in TP2 and are not included in the TP2 full analysis set.

Groups - Participants with Moderate Chronic Pain

Demographics & Baseline Pain Characteristics *

PIPE-791 (N=21)

Placebo (N=22)

Total (N=43)

Age (years)

57.1 (10.2)

57.9 (8.8)

57.5 (9.4)

Female Sex n (%)

11 (52.4%)

14 (63.6%)

25 (58.1%)

BMI (kg/m2)

30.7 (4.7)

31.3 (5.2)

31.0 (4.9)

Indication n (%)

COAP

11 (52.4%)

12 (54.5%)

23 (53.5%)

CLBP

10 (47.6%)

10 (45.5%)

20 (46.5%)

Duration of Primary Pain Diagnosis (Years)

11.2 (11.7)

10.0 (9.8)

10.6 (10.7)

Baseline VAS † Score

58.2 (11.7)

60.6 (11.5)

59.4 (11.5)

Baseline PCS † Total Score

16.9 (10.1)

16.6 (12.6)

16.7 (11.3)

*Values are reported as mean (SD) unless otherwise noted

† VAS = Visual Analog Scale; PCS = Pain Catastrophizing Scale

The most common TEAEs were headache (n=3) and fatigue (n=2)

No clinically meaningful changes in laboratory values and ECG findings across treatment groups

No clinically meaningful changes in vital signs, including mean changes in BP or clinically-relevant orthostatic events

Placebo

PIPE-791

Placebo

PIPE-791

Placebo

PIPE-791

Placebo

160

Systolic BP (mmHg)

140

120

100

Baseline Day 8

End of TP1*

Day 36

End of TP2

*PIPE-791 and Placebo positions reverse following End of TP1 as treatment assignments switch between periods in this crossover design.

Mean Change from Baseline (95% CI) in Weekly Average of Average Daily Pain (TP1 and TP2)

Mean (95% CI) Change from Baseline

0.4

0.0

-0.4

-0.8

-1.2

-1.6

-2.0

-2.4

-2.8

COAP - TP1

-0.51

-0.86

-1.32

-1.50

-1.53

-1.6

-1.2

-1.3

Baseline Week 1 Week 2 Week 3 End TP1

0.4

Mean (95% CI) Change from Baseline

0.0

-0.4

-0.8

-1.2

-1.6

-2.0

-2.4

-2.8

COAP - TP2

-0.32

-0.65

-0.56

-0.74

-0.92

-0.85

-0.96

-1.42

Baseline Week 5 Week 6 Week 7 End TP2

Mean Change from Baseline (95% CI) in Weekly Average of Worst Pain (TP1 and TP2)

1.2

Mean (95% CI) Change from Baseline

0.8

0.4

0.0

-0.4

-0.8

-1.2

-1.6

-2.0

-2.4

-2.8

-3.2

-3.6

COAP - TP1

-0.36

-0.66

-1.13

-1.00

-1.36

-1.9

Baseline Week 1 Week 2 Week 3 End TP1

1.2

Mean (95% CI) Change from Baseline

0.8

0.4

0.0

-0.4

-0.8

-1.2

-1.6

-2.0

-2.4

-2.8

-3.2

-3.6

COAP - TP2

-0.05

-0.52

-1.00

-0.81

-1.1

-0.7

-0.5

Baseline Week 5 Week 6 Week 7 End TP2

30% ≥ Greater Reduction From Baseline In Weekly Average of

COAP

60%

45.5%

44.4%

40%

27.3%

20%

End of TP1

End of TP2

Treatment Period Endpoint

PIPE-791 (n=11) Placebo (n=11)

Percentage of Responders (%)

Average Daily PI-NRS (COAP at End of TP1 & TP2)

Modified KOOS in COAP

Treatment Period 1

PIPE-791

Placebo

(N = 11)

Baseline Modified KOOS*

59.36 (9.65)

54.28 (15.39)

Change From Baseline

+10.56

+6.28

95% CI †

(3.62, 17.50)

(-2.63, 15.20)

Treatment Period 2

PIPE-791

Crossover Placebo

(N = 11)

(N = 10)

Baseline Modified KOOS*

60.56 (20.86)

71.91 (11.40)

Change From Baseline

+15.78

+3.53

95% CI †

(7.86, 23.69)

(-1.53, 8.59)

In this study only the activities of daily living function domain of the KOOS was administered

* Reported as mean (SD) of the last value before first dose of treatment period

† Reported as the Mean (CI) of change from day 1 to week 4 (TP1) or week 4 to week 8 (TP2)

TP1

COAP

CLBP

Average Daily Pain

PIPE-791 (N= 11)

Placebo (N =11)

PIPE-791 (N = 10)

Placebo (N = 10)

Baseline Weekly Average PI-NRS *

5.58 (1.21)

6.23 (1.43)

5.60 (1.27)

5.57 (1.50)

Change From Baseline

95% CI †

-1.60

(-2.49, -0.72)

-1.27

(-2.15, -0.39)

-1.33

(-1.83, -0.84)

-0.55

(-1.33, 0.22)

Worst Daily Pain

PIPE-791

Placebo

PIPE-791

Placebo

Baseline Weekly Average PI-NRS *

6.52 (0.89)

6.79 (1.34)

6.51 (1.21)

6.31 (1.31)

Change From Baseline

95% CI †

-1.99

(-3.30, -0.68)

-1.00

(-2.05, 0.05)

-1.28

(-1.85, -0.70)

-0.53

(-1.37, 0.32)

* Reported as mean (SD) of the daily average or the worst daily PI-NRS scores for the 7 days preceding randomization

† Reported as the mean change from Baseline in the weekly average of the daily average PI-NRS scores or worst daily PI-NRS scores, 95% Confidence Interval (CI), to End of Treatment Period 1 (Week 4)

TP2

COAP

CLBP

Average Daily Pain

PIPE-791 (N = 11)

Crossover Placebo (N = 10)

PIPE-791 (N = 9)

Crossover Placebo (N = 10)

Baseline Weekly Average PI-NRS *

4.96 (2.21)

3.56 (1.45)

4.72 (1.89)

4.75 (1.81)

Change From Baseline

95% CI †

-1.42

(-2.28, -0.56)

-0.74

(-1.83, 0.35)

0.13

(-0.68, 0.94)

-0.55

(-2.38, 1.29)

Worst Daily Pain

PIPE-791

Crossover Placebo

PIPE-791

Crossover Placebo

Baseline Weekly Average PI-NRS *

5.78 (2.22)

4.16 (1.57)

5.50 (1.94)

5.57 (1.73)

Change From Baseline

95% CI †

-1.17

(-2.15, -0.19)

-0.52

(-2.02, 0.97)

-0.14

(-1.16, 0.87)

-0.64

(-2.50, 1.21)

* Reported as mean (SD) of the daily average or the worst daily PI-NRS scores for the 7 days preceding Week 5

Fibrosis

LPA1 clinical validation in IPF/PPF

Differentiated profile including target coverage and tolerability

Brain penetrance may address fibrosis and pain burden including comorbid age-related pain (OA, CLBP) and pain components of ILDs (RA-ILD, SSc-ILD)

Chronic Pain

Novel, non-opioid mechanism targeting LPA1-driven peripheral and central sensitization

Encouraging safety and early efficacy signals

Ongoing evaluation to assess next steps in chronic pain indications for potential future development

PIPE-791 may address both fibrotic disease progression and the

pain/quality of life (QOL) burden experienced by pulmonary fibrosis patients

PIPE-791 Phase 1b Chronic Pain Trial Topline Data Supplemental Information

April 30, 2026

Disclaimer

Contineum Therapeutics Inc. published this content on April 30, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 30, 2026 at 21:48 UTC.